Gastroenterology
Model for end-stage liver disease-3.0 vs. model for end-stage liver disease-sodium: mortality prediction in Korea
Jeong Han Kim, Yong Joon Cho, Won Hyeok Choe, So Young Kwon, Byung-Chul Yoo
Korean J Intern Med. 2024;39(2):248-260. Published online February 1, 2024
Background/Aims: The model for end-stage liver disease (MELD) serves as an indicator for short-term mortality among patients diagnosed with liver cirrhosis (LC) and is used to prioritize patients for liver transplantation. In 2021, the updated version of MELD, MELD-3.0, was introduced to improve the..
|
|
Comparison of the efficacy and safety of direct-acting antiviral therapy with or without hepatitis C-related hepatocellular carcinoma
Byung Soo Kwan, Jeong Han Kim, Seong Jun Park, Won Hyeok Choe, So Young Kwon, Byung-Chul Yoo
Korean J Intern Med. 2021;36(2):292-304. Published online April 3, 2020
Background/Aims: Chronic hepatitis C (CHC) treatment has dramatically improved since direct-acting antiviral (DAA) therapy was introduced. However, the use of DAA therapy in CHC patients with hepatocellular carcinoma (HCC) remains controversial. We investigated the DAA treatment response in CHC pati..
|
|
Prognostic impact of hepatitis B or C on intrahepatic cholangiocarcinoma
Jung Woong Seo, Byung Soo Kwan, Young Koog Cheon, Tae Yoon Lee, Chan Sup Shim, So Young Kwon, Won Hyeok Choe, Byung Chul Yoo, Jeong Min Yoon, Jung Hoon Lee
Korean J Intern Med. 2020;35(3):566-573. Published online January 10, 2020
Background/Aims: Intrahepatic cholangiocarcinoma (ICC) is the second-most common primary liver malignancy, arising from the peripheral intrahepatic bile duct epithelium. Hepatitis B virus (HBV) or hepatitis C virus (HCV) may be involved in the development of ICC. We explored the prognostic value of ..
|
|
|
Gastroenterology
Incidence of and risk factors for thyroid dysfunction during peginterferon α and ribavirin treatment in patients with chronic hepatitis C
Yong Hwang, Won Kim, So Young Kwon, Hyung Min Yu, Jeong Han Kim, Won Hyeok Choe
Korean J Intern Med. 2015;30(6):792-800. Published online October 30, 2015
Background/Aims: Thyroid dysfunction (TD) is more likely to occur in patients with chronic hepatitis C (CHC) and is particularly associated with interferon (IFN) treatment. The purpose of this study was to investigate the incidence, outcomes, and risk factors for TD during pegylated interferon (PEG-..
|
|
Role of TGF - β1 and TGF - β Type 2 Receptor in Gastric Cancer
Dong Il Park, Hee Jung Son, Sang Yong Song, Won Hyeok Choe, Yun Jeong Lim, Sang Jong Park, Jae J. Kim, Young Ho Kim, Poong Lyul Rhee, Seung Woon Paik, Jong Chul Rhee, Kyoo Wan Choi
Korean J Intern Med. 2002;17(3):160-166. Published online September 1, 2002
|
|
|